A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Registration Number
- NCT00134147
- Lead Sponsor
- Pfizer
- Brief Summary
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1100
Inclusion Criteria
- Diabetes mellitus Type 2
- Failing two or more oral anti-diabetic agents
Exclusion Criteria
- Asthma, COPD
- Smoking
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Glycosylated hemoglobin
- Secondary Outcome Measures
Name Time Method Percent of patients achieving good control of fasting glucose and lipids Rate of hypoglycemia Changes in body weight Patient satisfaction Safety based on adverse events reported and laboratory tests
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇬🇧York, United Kingdom